Amol Akhade: New HER2-targeted therapy breakthrough in NSCLC
Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“New HER2-Targeted Therapy Breakthrough in NSCLC!
Zongertinib (BI 1810631) – a new, oral, HER2-selective tyrosine kinase inhibitor – is showing very promising results in patients with HER2-mutant non–small cell lung cancer (NSCLC)!
Here are the key highlights from the Phase 1b Beamion LUNG-1 trial:
Key Clinical Outcomes:
- Objective Response Rate (ORR): 71%
- Median Progression-Free Survival (PFS): 12.4 months
- Durable responses observed
- Active in brain metastases (Systemic ORR 64%, Intracranial ORR 41%)
- No cases of drug-related interstitial lung disease (ILD) reported!
- Low incidence of grade ≥3 adverse events (mainly reversible LFT elevations)
Mechanism of Action:
- Zongertinib is a HER2-selective irreversible TKI, sparing EGFR –
- Result: Reduced risk of diarrhea and rash compared to older pan-HER inhibitors.
- Action: Blocks HER2-driven tumor growth at the kinase level.
Clinical Dosing:
- 120 mg orally once daily (as selected from Phase 1b study).
Comparison vs existing therapy:
- When compared with trastuzumab deruxtecan (DESTINY-Lung01/02 studies), Zongertinib demonstrated:
Higher ORR Longer PFS No ILD concerns Lower toxicity profile
Developer: Boehringer Ingelheim
Takeaway:
- Zongertinib shows the potential to reshape the treatment landscape for HER2-mutant NSCLC – especially important for patients at risk of ILD or with brain metastases.
Excited to see how the upcoming Beamion LUNG-2 Phase 3 trial confirms these findings!
Swipe through the attached images:
1. Clinical Comparison Table
2. Mechanism of Action and Key Facts.”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023